Chimeric HIV-1 containing SIV matrix exhibit enhanced assembly in murine cells and replicate in a cell-type-dependent manner in human T cells  by Chen, Ping et al.
006) 1–12
www.elsevier.com/locate/yviroVirology 349 (2Chimeric HIV-1 containing SIV matrix exhibit enhanced assembly in murine
cells and replicate in a cell-type-dependent manner in human T cells
Ping Chen, Wolfgang Hübner, Kareen Riviere, Yu-Xin Liu, Benjamin K. Chen ⁎
Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, One Gustave Levy Place Box 1215, New York, NY 10029, USA
Received 14 September 2005; returned to author for revision 26 October 2005; accepted 8 February 2006
Available online 23 March 2006Abstract
Murine fibroblasts expressing viral receptors and human cyclin T1 allow HIV-1 entry and viral gene expression but do not support efficient
assembly. A chimeric HIV-1 carrying a non-homologous matrix (MA) from murine leukemia virus in place of HIV-1 MA can assemble efficiently
in murine cells, yet has poor infectivity. Here, we assess the ability of a homologous MA from SIV MAC239 to complement assembly and
infection in chimeric viruses designated SHIV(MA). The resulting SHIV(MA) chimeras produce more virus than native HIV-1 when transfected
into murine cells. SHIV(MA) exhibits cell-type-specific replication in human T cell lines, replicating well in MT4 cells and poorly in Jurkat cells
due to an incompatibility with the HIV-1 Env. The infectivity defects of SHIV(MA) are rescued by pseudotyping with VSV-G but not by
truncation of the cytoplasmic tail of Env. Passage of SHIV(MA) in Jurkat cells produces variants with improved Env incorporation and improved
replication in Jurkat but not in 3T3 TXC cells. The results indicate that cell-type-specific, or species-specific, host factors interact with MA to
modulate the efficiency of assembly and its compatibility with Env. With additional selection, SIV/HIV-1 chimeras may be useful for the
development of murine models of lentiviral infection.
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The MA domain of Gag is responsible for targeting HIV-1
assembly to specific membrane compartments in the cell (Facke
et al., 1993; Freed et al., 1994). In addition, it plays a key role in
recruiting Env to make infectious virus particles. In murine
fibroblasts, the targeting of Gag to the plasma membrane is
inefficient, resulting in poor virus production (Bieniasz and
Cullen, 2000; Garber et al., 1998; Mariani et al., 2000). In
murine cells, the p55 Gag precursor accumulates in an
unprocessed form and fails to associate efficiently with the
plasma membrane (Bieniasz and Cullen, 2000; Koito et al.,
2003; Reed et al., 2002; Swanson et al., 2004).
MA plays an important role in this murine cell phenotype.
The membrane binding activity of MA is thought to be
regulated during viral assembly by a myristoyl switch
mechanism (Paillart and Gottlinger, 1999; Spearman et al.,⁎ Corresponding author. Fax: +1 212 849 2525.
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doi:10.1016/j.virol.2006.02.0221997; Tang et al., 2004). The poor association of Gag with the
plasma membrane in murine cells suggests that the activation
of the membrane binding activity of the MA domain fails to
occur in these cells (Koito et al., 2003; Swanson et al., 2004).
We and others have found that replacement of the HIV-1 MA
domain with the murine leukemia virus (MuLV) MA domain
in a full-length proviral clone of HIV-1 significantly enhances
the ability of Gag to localize into punctate structures at the
plasma membrane and to assemble into virus particles (Chen et
al., 2001; Reed et al., 2002). These experiments demonstrate
that changing the MA domain with a functional homologue
from a distantly related virus can enhance the efficiency of
viral assembly in a cell-type-dependent manner. The ability of
these MHIV(MA) chimeras to replicate in human cells was
limited in part by poor incorporation of HIV-1 Env into virus.
MHIV(MA) chimeras require a deletion of the Env cytoplas-
mic tail to exhibit low-level infectivity and replicated weakly
only in MT4 cells after prolonged culture (Chen et al., 2001;
Reed et al., 2002). Thus, the MLV MA complements assembly
functions of HIV-1 MA but poorly complements other MA
functions.
Fig. 1. Replacement of the MA domain of HIV-1 with the well-conserved SIV
MA sequence. (A) Primary sequence alignment of SIVand HIV-1 MA domains
shows high sequence conservation. Identical residues are boxed in yellow.
Secondary structure is indicated by helical domains H1 through H5 in HIV-1 and
SIV MA. The beta turn sequence in SIV is also indicated. (B) Ribbon diagram
representing a structural alignment of alpha carbon backbone of SIV and HIV-1
MA domains reveals a high structural similarity. Superimposition of SIV MA
(Rao et al., 1995) and HIV-1 MA (Tang et al., 2002) structures was produced
using the UCSF Chimera package from the Computer Graphics Laboratory,
University of California, San Francisco (Pettersen et al., 2004). (C) Schematic
illustration of the design of two HIV-1 MA-chimeric viruses, SHIV(MA) and
SHIV(MA N1–96), which respectively replace all or only the most conserved
sequences of HIV-1 MA with sequences from SIV MAC 239 MA. Design of
second generation MLV MA chimeras MHIV(MA)v2 and MHIV(MA12)v2 are
similar to those previously published (Chen et al., 2001) with the insertion of a
native HIV MA-CA cleavage site (indicated by the sequence SQNY^PIVQ) at
the boundary of the MLV MA and the HIV CA in MHIV(MA)v2, or between
MA and p12 in MHIV(MA12)v2.
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inability of HIV-1 to assemble in murine cells. Experiments
with human–murine heterokaryons suggest that the poor
efficiency of assembly in murine cells is due to the absence of
a species-specific cofactor(s) (Bieniasz and Cullen, 2000;
Mariani et al., 2001). Other experiments focusing on the
efficiency of splicing in murine cells have found that the human
splicing regulatory protein, p32, can enhance assembly by
increasing Gag production in murine cells (Zheng et al., 2003).
Another report indicates that the RNA export pathway of the
Gag-encoding RNA influences the efficiency of HIV-1
assembly in murine cells, in a manner that is independent of
Gag expression levels (Swanson et al., 2004).
Host restriction of viral infection is frequently determined by
very minor sequence differences in viral or host proteins. For
example, a single amino acid substitution in the murine cyclin
T1 protein is sufficient to change the inactive mouse protein into
an efficient HIV-1 Tat cofactor (Garber et al., 1998). Single
amino acid differences in the antiviral APOBEC3G protein are
responsible for the inability of HIV-1 Vif to inactivate the
simian version of the gene (Bogerd et al., 2004; Mangeat et al.,
2004; Schrofelbauer et al., 2004). Minor sequence differences in
the CA domain of Gag are responsible for the poor ability of
HIV-1 to infect old world monkey cells (Hatziioannou et al.,
2004; Ikeda et al., 2004). While the SIV MA domain is highly
related to HIV-1 MA, some reports suggest that the SIV MA
domain may have a greater ability to support assembly
independently from the rest of Gag (Giddings et al., 1998;
Gonzalez et al., 1993). Therefore, we were interested in
determining whether the MA domain from SIV MAC239 can
complement assembly functions in human or murine cells in the
context of HIV-1 chimeras. The extent to which the SIV MA
complements HIV-1 MA functions provides insights into the
interactions of MA with both viral and host factors.
In this report, we examined chimeric HIV-1 molecular clones
carrying SIV MAC 239 MA in place of HIV-1 MA. When
pseudotyped in murine cells, SHIV(MA) was able to produce
greater levels of virus. Furthermore, these SHIV(MA) chimeras
replicated in a cell-type-specific manner in human T cells and
could be adapted to replicate efficiently in Jurkat T cells, yet
they did not replicate in multiple rounds in murine fibroblasts.
Replacement of the sequences of HIV-1 MAwith SIV MA has
cell-type-specific effects upon both assembly and Env
incorporation.
Results
SHIV(MA) chimeric virus strategy, sequence conservation, and
structural alignment
The amino acid sequences of HIV-1 and SIV MA are
homologous and are believed to assume similar structures (Hill
et al., 1996; Massiah et al., 1994; Matthews et al., 1994; Rao et
al., 1995). Sequence comparisons at the amino acid level show
that the first 96 amino acids are well conserved with SIV MAC
239 MA and HIV(NL4-3) MA sharing 58% identity (Fig. 1A).
Structures of both protein domains can be readily aligned. Aribbon diagram of the aligned alpha carbon backbones shows
that they fold into very similar structures (Fig. 1B) (Hill et al.,
1996; Rao et al., 1995). The C-terminal 30 amino acids of HIV-
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extended helix, whereas in SIV, this region forms a beta turn.
Studies on the isolated SIVMA domain suggest that despite this
high similarity to HIV-1 MA, it differs from HIV-1 MA in its
ability to assemble autonomously into virus like particles
(Giddings et al., 1998; Gonzalez et al., 1993). We were
therefore interested in understanding how well the SIV MA
domain would function in place of HIV-1 MA in full-length
proviral constructs.
Two SHIV(MA) chimeric viruses were created to test the
ability of the MA from SIV MAC239 to enhance assembly in
murine cells and to examine its compatibility within an HIV-1
genome (Fig. 1C). The first construct, SHIV(MA), carried the
full SIV MA domain in place of the HIV-1 MA domain. A
second chimera, SHIV(MA N1–96), replaced only the
conserved N-terminal 96 amino acids of SIV MA in place of
a similar portion of HIV-1 MA while maintaining the native
HIV-1 MA C-terminus. Because the presence of the cytoplas-
mic tail of Env can interfere with Env incorporation in MA
chimeras (Chen et al., 2001; Reed et al., 2002), we also created
variants of these constructs with a deletion of the last 144 amino
acids of the Env cytoplasmic tail.
SIV MA complements HIV-1 assembly functions in human cells
Transfection of SHIV(MA) chimeras into human 293T cells
showed that both SHIV(MA) and SHIV(MA N1–96) produced
a p55 precursor of a similar size to native HIV-1 p55 (Fig. 2A,
lanes 2 and 3). Proteolytic processing of both SHIV(MA) Gags
associated with the cell lysates also appeared similar to native
Gag. To compare the expression and processing of SHIV(MA)
chimeras with other MA chimeras, we tested the chimeras
MHIV(MA)v2 and MHIV(MA12)v2 (Fig. 1C), which carry the
MLVMA domain or the MLVMA and p12 domains in place of
HIV-1 MA (Chen et al., 2001). Both MLV MA chimeric GagFig. 2. Replacement of the HIVMAwith SIVMA complements assembly in human 2
human 293T cells transfected with the indicated proviral constructs, examining the c
viruses. (B) Anti-HIV-1 Western blot analysis of sucrose-pelleted virus particles fr
supernatants from transfected 293T cells versus the levels p24 in the transfected 293T
pelleted through a 20% sucrose cushion prior to analysis.proteins were also expressed well, with Gag precursor and p24
evident in the Western analysis of transfected 293T cell lysates
(Fig. 2A, lanes 4 and 5).
Western blot analysis of the sucrose-pelleted viral super-
natants from transfected 293T cells shows that both SHIV(MA)
constructs produced virus particles with a similar efficiency to
native HIV-1 and both MHIV(MA) chimeras (Fig. 2B).
Quantitative p24 ELISA of the sucrose-pelleted supernatants
shows that the SHIV(MA) and SHIV(MA N1–96) chimeras
produced particles within two-fold of native HIV-1 and both
MHIV(MA) chimeras in 293T cells (Fig. 2C).
SIV MA enhances assembly of HIV-1 in murine cells
In transfected murine 3T3 TXC cells (Chen et al., 2001),
which stably express the human genes for CD4, CXCR4, and
CyclinT1, the SHIV(MA) and SHIV(MA N1–96) Gag pre-
cursors were both produced at a level similar to native HIV-1
(Fig. 3A). Native HIV-1, SHIV(MA), and SHIV(MA N1–96)
all showed a dominant p55 precursor band. A faint p24 band
is present in the SHIV(MA) and SHIV(MA N1–96) lanes that
is not observed in the HIV-1 lane. In comparison, constructs
carrying murine leukemia virus MA, MHIV(MA)v2, or both
MLV MA and p12, MHIV(MA12)v2, expressed lower levels
of steady-state Gag precursor in the cells and also gave rise to
a p24 band (Fig. 3A, lanes 4 and 5). In these lanes, the
MHIV chimeras had a lower levels of precursor Gag associated
with the cell lysates as compared to HIV-1 or either SHIV(MA)
chimera.
Western blot of the sucrose-pelleted virus particles showed
that both the SHIV(MA) and SHIV(MA N1–96) viruses
produced more p24 than native HIV-1 in murine cells (Fig.
3B, lanes 8 and 9), whereas little virus was released from the
cells transfected with native HIV-1. As a basis for comparison,
MHIV(MA)v2 and MHIV(MA12)v2 produced higher levels of93Tcells. (A) Anti-HIV-1Western blot analysis of HIV-1 proteins produced from
ell lysates. Native HIV-1 (molecular clone NL4-3) is compared to MA chimeric
om transfected 293T cell supernatants. (C) Comparison of p24 levels in viral
cell lysates. P24 levels were determined by quantitative p24 ELISA. Virus was
Fig. 3. Replacement of the HIV MAwith SIV MA enhances assembly of chimeric viruses in murine 3T3 TXC cells. (A) Anti-HIV-1 Western blot analysis of HIV-1
proteins produced from 3T3 TXC cells transfected with the indicated proviral constructs, examining the cell lysates. Native HIV-1 (molecular clone NL4-3) is
compared to MA chimeric viruses. (B) Anti-HIV-1 Western blot analysis of sucrose pelleted virus particles from transfected 3T3 TXC cell supernatants. (C)
Comparison of p24 levels in viral supernatants from transfected 3T3 TXC cells versus the levels p24 in the transfected 3T3 TXC cell lysates. P24 levels were
determined by quantitative p24 ELISA. Virus was pelleted through a 20% sucrose cushion prior to analysis.
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measured by quantitative p24 ELISA, 3T3 TXC cells transfected
with SHIV(MA) and SHIV(MAN1–96) each released 20- to 30-
fold more virus than native HIV-1 (Fig. 3C). The MHIV(MA)
and MHIV(MA12) constructs released 60-fold more p24 than
native HIV-1 (Fig. 3C). The magnitude of the improvement in
virus particle production by both SHIV(MA) chimeras was
comparable to that observed from the MLV MA-carrying
chimeras, MHIV(MA)v2 and MHIV(MA12)v2.
To examine the fraction of sucrose pelleted p24 antigen
released from cells relative to that retained in the cell at steady
state, we divided the cell-associated p24 levels by the virus-
associated p24 levels to come up with a relative antigen
retention to release (ARR) ratio (Table 1). The ARR ratios for
all five constructs in 293T cells were all fairly close to 0.6,
whereas the ARR ratios were markedly different between viral
constructs in the 3T3 TXC cells. HIV-1 antigen was highly
retained in the 3T3 TXC cells with an ARR ratio of 17.71,
whereas the SHIV(MA) and SHIV(MA N1–96) chimeras had
ratios of 0.57 and 0.54. MHIV(MA)v2 and MHIV(MA12)v2
retained even less antigen (Fig. 3A, lanes 4 and 5; Fig. 3C), and
as a result had very low ARR ratios of 0.09 and 0.10
respectively.Table 1
p24 ELISA in cell lysates/virus particles, analysis of 293T and 3T3 TXC cells
Relative antigen retention to release ratio (CL/VP)
293T 3T3 TXC
HIV-1 0.64 17.71
SHIV(MA) 0.60 0.57
SHIV(MA N1-96) 0.63 0.54
MHIV(MA) 0.54 0.09
MHIV(MA12) 0.59 0.10SHIV(MA) and SHIV(MA N1–96) replicate in MT4 cells but
not in Jurkat cells
Previous studies with MLV MA chimeras have found the
viruses to be attenuated in their ability to replicate in human T
cell lines. To examine the ability of SHIV(MA) chimeras to
replicate in T cell lines, we produced viruses by transient
transfection of 293T cells. Supernatants containing 15 ng of
p24 CA antigen from each virus were used to infect
transformed CD4+ T cell lines, MT4, or Jurkat. MT4 cells
have been shown to support the replication of viruses that lack
the cytoplasmic tail of Env (Murakami and Freed, 2000).
Native HIV-1 replicated in MT4 cells with a rapid peak in p24
antigen detected at 3 days (Fig. 4A). Strong cytopathic effects
were observed in these cells concomitant with peak virus
production. At 7 days post-infection, both the SHIV(MA) and
SHIV(MA N1–96) reached high peak p24 levels comparable to
those of native HIV-1 (Fig. 4A). The infections of SHIV(MA)
and SHIV(MA N1–96) also exhibited strong cytopathic effects
coincident with peak antigen production. This 4-day delay to
peak p24 levels in both SHIV(MA) and SHIV(MA N1–96)
infections was much shorter than the 4-week culture required
of MHIV (Reed et al., 2002). Furthermore, replication of the
SHIV(MA) chimeras did not require the deletion of the Env
cytoplasmic tail, as is necessary for replication of MHIV
(Reed et al., 2002) or viruses deleted in the globular head of
MA (Reil et al., 1998). Deletion of the cytoplasmic tail
slowed the replication of non-chimeric HIV-1, but did not
improve the replication of SHIV(MA) or SHIV(MA N1–96)
viruses (Fig. 4A).
HIV-1 replicated in Jurkat cells with a peak virus
production at 7 days post-infection. In contrast, SHIV(MA)
and SHIV(MA N1–96) did not replicate in Jurkat cells when
infected with a comparable dose of virus (Fig. 4B). No
cytopathic effects were observed in a 2-week period following
Fig. 4. Cell-type-dependent replication of SHIV(MA) and SHIV(MA N1–96) in
human T cell lines. (A) MT4 cells, or (B) Jurkat cells, were infected with viral
supernatants containing 15 ng of p24 produced in human 293T cells. Virus
particle production in cell supernatants was monitored by p24 ELISA.
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replicate efficiently in MT4, but not in Jurkat cells, has been
observed for viruses with mutations in the cytoplasmic tail of
Env (Akari et al., 2000; Murakami and Freed, 2000). Deletion of
the cytoplasmic tail of Env abolished replication of native HIV-1Fig. 5. Single round infectivity of SHIV(MA) and SHIV(MA N1–96) is less efficie
Infectivity of virus produced by transfection of 293T cells with indicated proviral con
GHOST indicator cell lines with virus produced in 293Tcells shows dose-dependent d
SHIV(MA N1–96). (C) Levels of pelletable gp120 are decreased in SHIV(MA) and
Env expression in the cell lysates (top) and purified virus particles (middle) isolated
allele of HIV Env, ΔCT. p24 in the purified virus particles was detected by anti-HIVin Jurkat cells (Fig. 4B), as previously reported (Murakami and
Freed, 2000). Our studies further found that the mutation did not
rescue replication of SHIV(MA) or SHIV(MA N1–96) (Fig.
4B). In previous studies (Akari et al., 2000; Murakami and
Freed, 2000), defects in infectivity correlated with decreased
levels of Env incorporation onto the virus particles. We therefore
examined the compatibility of the SIV MAwith the HIV-1 Env
in our SHIV(MA) chimeras.
Poor replication in Jurkat correlates with impaired single
round infectivity of SHIV(MA) constructs and impaired Env
incorporation
To examine the compatibility of the SHIV(MA) chimeric
Gag proteins with the HIV-1 Env, we tested these constructs
for their ability to infect CD4-expressing HeLa MAGI HIV
indicator cell line in a single round of infection. The
infectivity of the SHIV(MA) and SHIV(MA N1–96) was
20- to 25-fold lower than native HIV-1 when the viruses were
produced with endogenously expressed HIV-1 Env and used
to infect HeLa MAGI cells (Fig. 5A). The deletion of the
cytoplasmic tail of Env diminished the infectivity of HIV-1
and did not improve the infectivity of SHIV(MA) or SHIV
(MA N1–96) (Fig. 5A). HeLa MAGI infectivity assays were
performed with a single dose of virus. We also infected CD4+
human osteosarcoma HIV indicator cell line, GHOST, which
is induced to express GFP upon infection with HIV-1. We
used flow cytometry to count the percentage of target cells
infected at varying viral inputs. These experiments showed a
linear relationship between dose and infectivity with the
native HIV-1 but little infectivity for either SHIV(MA)
chimera (Fig. 5B). The infectivity profile of SHIV(MA)
chimeras in both HeLa MAGI and GHOST indicator cells
correlated with their poor ability to replicate in Jurkat cells
(Fig. 4B).nt than native HIV-1 and correlates with altered Env in viral supernatants. (A
structs was assessed by infection of HeLa MAGI indicator cells. (B) Infection o
ecrease in infectivity from native HIV-1 and low infectivity from SHIV(MA) and
SHIV(MA N1–96) viral preparations. Anti-HIV-1 Env Western blot examining
from transfected 293T cells. Asterisk (*) indicates the position of the truncated
-1 antiserum (bottom).)
f
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the efficiency of Env incorporation (Dorfman et al., 1994; Freed
and Martin, 1995), we examined the ability of SHIV(MA) and
SHIV(MA N1–96) viruses to incorporate native HIV-1 Env or
ΔCT Env. 293T cells transfected with native HIV-1, SHIV(MA)
and SHIV(MA N1–96) proviral constructs all expressed similar
levels of steady-state Env (Fig. 5C, top). The smaller molecular
weight of the ΔCT constructs carrying the deletion of the
cytoplasmic tail was apparent in these blots. Western analysis
of virus particles pelleted through 20% sucrose cushions
revealed somewhat lower levels of total Env associated with
both SHIV(MA) viruses (Fig. 5C, middle). In particular, the
band for gp120 Env was diminished to a greater extent in both
the SHIV(MA) and SHIV(MA N1–96) relative to native HIV-1
(Fig. 5C, middle). Deletion of the cytoplasmic tail increased the
levels of the gp120 that pelleted with the SHIV(MA) and
SHIV(MA N1–96) virus particles; however, this increase was
not associated with increased infectivity (Fig. 5A). As a
control, the levels of p24 CA found in the viral supernatants
were not affected by the deletion of the cytoplasmic tail of Env
(Fig. 5C, bottom).
Rescue of infectivity of SHIV(MA) or SHIV(MA N1–96) by
VSV-G pseudotyping
To further examine whether compatibility of SIV MA with
HIV-1 Env is a major limiting factor in the infectivity of the
SHIV(MA) chimeras, we pseudotyped the viruses by cotrans-
fecting the full-length proviral constructs with VSV-G expres-
sion plasmid during production in 293T cells. SHIV(MA) or
SHIV(MA N1–96) pseudotyped viruses were rescued to the
level of VSV-G pseudotyped HIV-1 when tested on HeLaMAGI
cells as the target cell (Fig. 6A). Titration of the VSV-G
pseudotyped virus on GHOST indicator cells showed that
pseudotyped SHIV(MA) and SHIV(MA N1–96) exhibited a
relative infectivity in GHOSTcells similar to that of native HIV-Fig. 6. Infectivity of the SHIV(MA) and SHIV(MA N1–96) can be rescued by pseud
produced in the presence or absence of VSV-G expression vector, pMD-G. Relative in
field (HPF). Infectivity results are representative of three independent experiments
GHOST cells shows infectivity comparable to pseudotyped native HIV-1.1 (Fig 6B). Therefore, the low infectivity of the SHIV(MA)
chimeras in HeLa MAGI or GHOST indicator cells can be
rescued by simple cotransfection of VSV-G during virus
production. These data suggest that the low infectivity of
SHIV(MA) and SHIV(MAN1–96) is largely attributable to Env
compatibility issues.
Selection of variants of SHIV(MA) and SHIV(MA N1–96) with
an improved ability to replicate in Jurkat cells
To select for SHIV(MA) variants with higher replicative
capacity in Jurkat cells, we pseudotyped the SHIV(MA) and
SHIV(MA N1–96) with VSV-G and used the viral super-
natants to infect Jurkat cells. This approach allowed a greater
number of viruses to infect in the initial round of infection
and, as a consequence, enhanced the probability that viruses
with favorable mutations were available for selection.
Because the VSV-G was provided in trans by transient
cotransfection, it enhanced the initial, but not subsequent,
rounds of infection. In these cultures, the SHIV(MA N1–96)
produced high titers of p24 antigen accompanied by strong
cytopathic effects after 21 days in culture (Fig. 7A). SHIV
(MA) construct also produced high levels of p24 after a
longer delay, peaking at nearly 31 days post-infection. When
viruses from this infection were passaged for a second round
in Jurkat cells (designated as p2), the delay in SHIV(MA)
replication was much shorter than the original infection (Fig.
7B). In the second passage, SHIV(MA N1–96)p2 produced a
peak titer only 2 days following native HIV-1 and exhibited
strong cytopathic effects. In Jurkat cells, SHIV(MA) p2
exhibited a 4-day delay relative to native HIV-1 and also
exhibited cytopathic effects. Subsequent passages (passage
three and four) of the viruses in Jurkat cells produced
SHIV(MA) and SHIV(MA N1–96) isolates that continued to
replicate with similar short delays relative to passaged HIV-1
(data not shown).otyping proviral construct with VSV-G. (A) Infectivity of SHIV(MA) chimeras
fectivity of viruses was calculated by counting of blue cell foci per high-powered
. (B) Titration of VSV-G pseudotyped SHIV(MA) and SHIV(MA N1–96) on
Fig. 7. Selection of SHIV(MA) and SHIV(MA N1–96) in Jurkat cells results in
viruses with improved replication in Jurkat cells but do not replicate efficiently
in 3T3 TXC cells. (A) Delayed replication of SHIV(MA) and SHIV(MA N1–
96) is detected in Jurkat cells when viruses are pseudotyped with VSV-G and
infected with viral supernatants containing 15 ng of p24. (B) Passage of viruses
in Jurkat cells results in improved replication of SHIV(MA)p2 and SHIV(MA
N1–96)p2. Supernatants containing 25 ng of each of the viruses produced at
peak of viral replication growth curve shown in panel A were used to infect
Jurkat cells. (C) Infection of 3T3 TXC cells with viruses selected by passage
(P4) in Jurkat cells does not greatly enhance infectivity on murine 3T3 TXC
cells. Supernatants containing 30 ng of p24 for each virus were used to infect
3T3 TXC cells. Cells were washed extensively after 12 h of exposure to the
virus, and virus production was monitored with p24 ELISA of samples at three
successive time points. AZT treatment (100 nM) was employed to confirm that
virus measured was a product of infection of 3T3 TXC cells.
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TXC cells and produce only low levels of virus
Because the SHIV(MA) chimeras assembled in murine cells
with higher efficiency when transfected, and a variant of these
viruses can replicate efficiently in human T cells, we then
tested whether passaged SHIV(MA) would show a greater
overall fitness during infection of 3T3 TXC cells. Infection ofthese cells with the passaged viruses (from passage 4), HIV-
1p4 and SHIV(MA N1–96)p4, transiently released low levels
p24, without evidence of multi-round replication in these cells
(Fig. 7C). The peak in p24 production occurs 24 to 48 h
following infection. The transient peak of p24 production from
the SHIV(MA N1–96)p4 is weak, yet only two-fold better than
the production from HIV-1p4. To ensure that the p24 released
from the cells was not due to carryover of the input virus, an
azidothymidine (AZT)-treated control was performed. The low
levels of p24 released from the 3T3 TXC cells were sensitive
to AZT, indicating that virus measured was produced from
newly infected 3T3 TXC cells. Although the SHIV(MA N1–
96)p4 virus was able to infect the 3T3 TXC cells, the p24
production was inefficient and unsustained.
Infectivity and Env incorporation on SHIV(MA) chimeras is
increased following selection in Jurkat cells
Titering p2-viruses on HeLa MAGI cells revealed that
their infectivity was improved relative to unpassaged viruses
(Fig. 8A) displaying an infectivity of 40% of control
passaged HIV-1 at highest p24 input. Titration of these passaged
viruses on GHOST indicator cells showed that the passaged
SHIV(MA) chimeras were improved in titer over unpassaged
virus (compared with Figs. 5 and 6), yet the passaged HIV-1
was still several-fold more infectious than SHIV(MA)p3 or
SHIV(MA N1–96)p3 (Fig. 8B).
To see if the levels of Env associated with the virus particles
changed following passage through Jurkat cells, we compared
the pelletable Env from viruses produced in 293T cells to the
Jurkat passaged viruses. An anti-gp120 Western blot of sucrose-
pelleted virus particles harvested from passage 2 shows that the
SHIV(MA) chimeric viruses were associated with increased
levels of pelletable Env to levels similar to that of native HIV-1
(Fig. 8C, top panel). In particular, a Western blot with anti-gp41
antibody showed that levels of gp41 in both SHIV(MA)
chimeras produced in 293T cells (p0) were lower than native
HIV-1, whereas the gp41 levels associated with the SHIV(MA)
chimeras were similar to HIV-1 after passage in Jurkat cells (p2)
(Fig. 8C, middle panel). This may indicate that improved
packaging of Env or enhanced processing of the gp160
precursor to gp41 and gp120 is responsible for the improved
infectivity of the SHIV(MA)p2 and SHIV(MA N1–96)p2. A
control immunoblot for p24 shows that the viral pellets from p0
and p2 contained similar levels of capsid antigen (Fig. 8C,
bottom panel).
To rule out cross-contamination of samples as an
explanation for the adaptive changes in Jurkat-passaged
SHIV(MA) and SHIV(MA N1–96) and to identify possible
compensatory mutations from the original sequence, we
isolated RNA from sucrose pelleted viruses and performed
direct sequencing of reverse transcriptase mediated PCR
products, initially across the entire gag and env open reading
frames. Initial sequencing determined that the entire gag from
SHIV(MA) or SHIV(MA N1–96) were identical to the input
viruses. Therefore, the increased replication of passaged
SHIV(MA) chimeras was not attributable to viral cross
Fig. 8. Infectivity of the SHIV(MA) chimeras passaged in Jurkat cells is increased on HeLa MAGI and GHOST cells and has greater levels of particle associated Env.
(A) Infectivity of passaged SHIV(MA)p2 and SHIV(MA N1–96)p2 on HeLa MAGI indicator cells. Cells were infected with 30 ng of p24 of each virus harvested at
peak of replication and stained with X-gal 48 h later. (B) Titration of SHIV(MA)p3, SHIV(MA N1–96)p3, and HIV-1p3 viruses recovered from passage 3 on Jurkat
cells were measured for p24 content and used to infect GHOST indicator cells at varying doses. (C) SHIV(MA)p2 and SHIV(MA N1–96)p2 passaged virus
incorporate more Env than non-passaged virus produced in 293T cells. Supernatants from non-passaged (p0) or passaged (p2) carrying equivalent levels of p24 were
pelleted by ultracentrifugation through 20% sucrose. Viral proteins were separated by SDS-PAGE followed by Western blot analysis using anti gp120 antibody (top),
anti-gp41 monoclonal antibody (middle) or anti-HIV-1 antiserum to detect p24 (bottom).
8 P. Chen et al. / Virology 349 (2006) 1–12contamination, a simple reversion to more HIV-like sequences
in MA, or a result of second site changes in other regions
within gag. Sequencing of SHIV(MA N1–96)p2 and p3 env
revealed a three nucleotide deletion resulting in deletion of
glutamate 265 (N-terminal to V3) in p3 viruses. There was no
evidence of deletion of the cytoplasmic tail that can occur
during selection of SIV in human cells (Kodama et al., 1989).
There were no missense changes in the cytoplasmic tail,
suggesting that alterations in the regions of Env that may
interact with MA are also not directly responsible for the
increased fitness of passaged SHIV(MA N1–96).
Additional sequencing of overlapping PCR products cover-
ing the open reading frames from gag through nef, spanning
8700 nucleotides, revealed changes to vpu (stop codons), the
ectodomain of env, and nef (Fig. 9). Based on this sequence
analysis, it is likely that mutation(s) outside of cytoplasmic tail
of Env or Gag is important for the enhanced fitness of the
passaged viruses. Alternatively, it is possible that mixed viral
populations present in the p3 virus or epigenetic changes are
responsible for the improved replication in Jurkat cells.
Identification of the key changes responsible for enhanced
replication in Jurkat cells will be best approached systematically
by creating full-length proviral clones.
Discussion
We have studied an MA-chimeric lentivirus to examine
how interactions between MA and host factors can regulate
assembly in different cell contexts. In particular, we have
examined whether MA-chimeric virus models support greater
assembly and replication in murine cells. Previous studies have
illustrated that a highly unrelated MA domain from the murine
C-type, simple retrovirus, MuLV, can complement the
assembly functions of HIV-1 MA in both human and murinecells when inserted in place of the HIV-1 MA sequence (Chen
et al., 2001; Reed et al., 2002). The resulting chimeric virus,
which we called MHIV(MA), assembled with a greatly
enhanced ability in murine cells but was impaired in its
replication. Here, we have found that replacing the HIV-1 MA
domain with a highly related sequence from another primate
lentivirus, SIV MAC239, also markedly enhanced assembly in
murine cells. Replacement of the most highly conserved
helical core (amino acids 1–96) of HIV-1 with that from SIV
MA was sufficient to improve the efficiency of assembly in
murine cells. This further supports the idea that HIV-1 MA
plays an important role in limiting the assembly of HIV-1 in
murine cells. Unlike the MHIV MA chimeras, we did not
observe major changes in the efficiency of Gag processing in
the SHIV(MA) chimeras. However, in comparison to our
previous studies with the MuLV MA domain, we found that
this exchange of lentiviral MA domains resulted in a chimeric
virus with greater ability to replicate in human T cell lines, but
not in murine 3T3 TXC cells. It is possible that other blocks to
efficient replication of SHIV(MA) may exist in these cells.
Although the HIV-1 MA and the SIV MA domain are
homologous peptides with similar structures, previous studies
show that they differ in their ability to participate in the
assembly process. Unlike HIV-1 MA, expression of an isolated
SIV MA protein, in the absence of C-terminal Gag sequences,
can form virus like particles that can even incorporate the SIV
Env (Giddings et al., 1998; Gonzalez et al., 1993). It is possible
that because the SIV MA domain carries additional basic
residues near its N-terminus, it may have a higher intrinsic
affinity for membranes. Despite these differences, when placed
within the context of HIV-1 Gag, the SIV MA did not increase
virus production in human 293T cells. Its positive effects on
mediating viral assembly were only apparent in murine cells,
suggesting that an interaction of the MA domain with the
Fig. 9. Genomic location of sequence changes identified by sequencing of PCR products from HIV-1p3 and SHIV(MAN1–96)p3. The nomenclature for the mutations
is as follows: the single letter abbreviation for the native amino acid, followed by its position within the protein, followed by the mutated amino acid. The gene in which
the mutation occurs is labeled below the mutation. No conservative changes were identified. Partial mutations with mixtures of two bases are indicated with an asterisk.
The region covered by RT-PCR mediated sequencing is indicated with the black bar on the bottom.
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Gag assembly.
Heterokaryon fusion experiments suggest that the block to
HIV-1 assembly may be caused by the absence of a factor
that is required for HIV-1 assembly (Bieniasz and Cullen,
2000; Mariani et al., 2001). Our studies of SHIV(MA)
chimeras further support the hypothesis that this putative
missing factor(s) may interact with MA. It has recently been
found that the MA domain of Gag can interact with the delta
subunit of the adapter protein complex 3 (AP-3δ), and that
this interaction is important for assembly of HIV-1 (Dong et
al., 2005). It will therefore be interesting to determine what
role AP-3, or other cellular factors, play in regulating the
location and efficiency of assembly of SIV or SHIV(MA)
chimeras. It is possible that sequence differences in MA that
enhance assembly may improve the ability of the chimeric
Gag protein to interact with a putative murine cofactor of
assembly. The high sequence similarity of SIV MA and HIV-
1 MA may allow us to map the structural features responsible
for enhanced assembly in murine cells. An approach that
investigates the ability of proteins to bind differentially to a
SHIV(MA) Gag, but not HIV-1 Gag, may identify key factors
that facilitate assembly in murine cells.
To further evaluate the promise of SHIV(MA) chimeras in
developing a mouse model, we tested the compatibility of the
SIV MA during viral replication. The MA domain of HIV-1
is intimately involved in recruiting the Env glycoprotein into
the virus particle through an interaction with the Env
cytoplasmic tail (Freed and Martin, 1996; Ono et al., 1997).
We found that the SHIV(MA) chimeric viruses were
replication competent in highly permissive MT4 cells, but
were less efficient at replication in Jurkat cells. Despite the
high sequence similarity of SIV MA and HIV-1 MA, the SIV
MA was poorly compatible with HIV-1 Env. Although some
Env was incorporated into these SHIV(MA) particles, it was
less efficient at infection of Jurkat, HeLa MAGI, or GHOST
indicator cells. We noticed in the two SHIV(MA) viruses that
relatively little pelletable Env was found in the processedgp120 form. This defect may in part be responsible for the
decreased infectivity of both SHIV(MA) chimeras on HeLa
MAGI cells and Jurkat cells. Complementing these viruses
with VSV-G rescued their infectivity. While deletion of
cytoplasmic tail appeared to improve the ratio of gp120 to
unprocessed precursor on SHIV(MA) chimeras, it did not
result in an increase in infectivity. This phenotype distin-
guishes the SHIV(MA) chimeras from the MHIV(MA) (Reed
et al., 2002) and ΔMA mutants (Reil et al., 1998), which both
require the ΔCT Env mutation to replicate. In comparison to
these other MA-mutant/chimeras, the Env incorporation
defect in SHIV(MA) was much less severe.
Cell-type-dependent replication has been observed for
viruses with deletions in the Env cytoplasmic tail and has
been proposed as evidence for the importance of cell-
specific factors in modulating Env incorporation (Akari et
al., 2000; Murakami and Freed, 2000). The ability of
unpassaged SHIV(MA) viruses to infect MT4 cells, but not
Jurkat cells, suggests that host factors regulate the
interaction between MA and Env. Selection of these viruses
for high-level replication in Jurkat cells improved the levels
of Env on virus particles and their infectivity. Unexpectedly,
our sequencing of the passaged viruses indicated that
sequences outside of Gag or the cytoplasmic tail of Env
may influence the compatibility of MA with replication in
Jurkat cells. Alternatively, complex mixtures of adaptive
changes in the viruses, or epigenetic alterations during
propagation in T cells, could be responsible for the adaptive
phenotype. It will be interesting to determine what genetic
loci in HIV may modulate the compatibility of MA and
Env. These studies will be facilitated by the creation of
full-length clones of the passaged viruses.
Additional selection of SHIV(MA) chimeras in murine
cells may identify HIV-1 variants with improved assembly
and improved infectivity in murine cells. If a variant can be
found to replicate in multiple rounds in murine cells, it may
provide a useful model for the infection of transgenic mice.
The continued study of these chimeras and their ability to
10 P. Chen et al. / Virology 349 (2006) 1–12replicate in various cell environments may help to identify the
host factors that regulate assembly, envelope incorporation
and viral infectivity.
Materials and methods
Plasmids, cell lines, and transfections
Chimeric proviral Gag constructs were produced by
modification of the HIV-1 proviral construct, pNL4-3 (Adachi
et al., 1986) inserting sequences from SIV MAC239 molecular
clone (Kestler et al., 1990; Regier and Desrosiers, 1990). PCR
based mutagenesis was employed to create SHIV(MA) and
SHIV(MA N1–96). The nucleotide sequence of the 5′ HIV-SIV
junction was 5′-CGGAGGCTAGAAGGAGAGAGatgggcgtga-
gaaactccgtc-3′ where uppercase letters represent HIV-1 derived
sequences and lowercase letters represent SIV derived
sequences. The 3′ junction for SHIV(MA) is represented by
the following oligo: 5′-tagcggcagaggaggaaattacCCTATAGTG-
CAGAACCTCCAGG-3′ and the 3′ junction for SHIV(MA
N1–96) is represented by the following oligo: 5′-tgcattcacgca-
gaagagaaagtgaaacacACCAAGGAAGCCTTAGATAAGATA-
GAGGAA-3′. Chimeric gag sequences were inserted into
pNL4-3 using unique BssHII and SpeI sites. Mutant proviral
clones with a deletion of the C-terminal 147 amino acids
referred to as ΔCT were constructed with the following
mutagenic oligo, 5′-GTACTTTCTATAGTGAATAGAGT-
TAGGtaGtaATATTCACCATTATCGTTTCAGACC-3′, where
the lowercase letters represent the mutations that insert a stop
codon into the env reading frame of molecular clone of HIV-1,
pNL4-3. MHIV(MA) studied in Chen et al. (2001) were
modified to encode an HIV-1 protease cleavage site that
replicates the native HIV-1 MA-CA junction between the MLV
MA and HIV-1 CA, designated MHIV(MA)v2. Another
construct, MHIV(MA12)v2, carries an HIV-1 MA-CA junc-
tional sequence between MLV MA and MLV p12. Nucleotide
sequences for the novel junctions created for each indicated
constructs are as follows (lowercase are MLV derived and
uppercase are HIV-derived sequences). In MHIV(MA)v2,
sequence of the MA-CA junction is as follows: 5′-
tcgaccccgcctcgatccAGCCAAAATTACCCTATAGTGCAG-3′.
In MHIV(MA12)v2, the following sequence inserts HIV-1
protease cleavage site between the MLV p15 and p12
sequences: 5′-tcgaccccgcctcgatccCAAAATTACCCTA-
TAGTGCAGccttctctaggcgccaaacc-3′. All PCR generated muta-
tions were confirmed by sequencing of the entire amplified
regions.
Human embryonic kidney cells expressing T antigen, 293T,
and NIH 3T3 cells expressing human CD4, CXCR4, and cyclin
T1 were previously described (Chen et al., 2001). Human 293T
cells were transfected with standard calcium phosphate methods
(Ausubel et al., 2003), and 3T3 TXC cells were transfected with
Lipofectamine 2000 (Invitrogen), according to manufacturers
instructions. HeLa MAGI indicator cells from Michael Emer-
man (Kimpton and Emerman, 1992) and CD4+ GFP-expressing
human osteosarcoma cell line, GHOST, from Vineet KewalRa-
mani and Dr. Dan Littman (Morner et al., 1999), were obtainedthrough the AIDS Research and Reference Reagent Program
(ARRRP).
Western blots, ELISA
Cell lysates were prepared by lysis of transfected cells in
1% triton lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA (TNE), 1% Triton X-100, and protease
inhibitor cocktail). Viral supernatants were pelleted by
ultracentrifugation for 2 h at 36,000 rpm in SW50.1 rotor
through a 20% sucrose cushion. Pelleted viruses were
resuspended in 1% Triton lysis buffer and proteins separated
by LDS PAGE, using 4-12% gradient NuPAGE Gels
(Invitrogen). Polyclonal human anti-HIV-1 patient immune
globulin, obtained from Alfred Prince through the ARRRP,
was diluted to 1:5000 for Western analyses. Polyclonal sheep
anti-HIV-1 Env, obtained from Michael Phelan through the
ARRRP, was diluted 1:2500 for Western analyses. Western
blots were developed with horseradish peroxidase coupled
secondary antibodies followed by Enhanced Chemilumines-
cence Assay (Amersham). Luminescence based ELISA assay
using commercial antibodies (International Enzymes) has
been previously described and provides a highly quantitative
assay with large dynamic range (McKeating et al., 1991;
Moore et al., 1990).
Infectivity assays, HeLa MAGI, and luciferase assays
Infectivity of virus was assessed by titering viruses on CD4+
HeLa MAGI cells (Kimpton and Emerman, 1992) or GHOST
cells (Morner et al., 1999). Cells were exposed to indicated
concentrations of virus in the presence of 4 μg/ml of polybrene
(Sigma) and washed 24 h post-infection. At 48 h post-infection,
cells were fixed and stained for beta-galactosidase activity in
situ for HeLa MAGI assays. The number of infectious blue foci
per high-powered field was counted and averaged across 6
random fields. For GHOST cell analysis, infected cells were
trypsinized, fixed in 4% paraformaldehyde, and GFP-expres-
sing infected cells were enumerated by flow cytometry.
Pseudotyped proviral constructs were produced by transient
transfection of 293T cells, cotransfecting proviral DNAwith an
equal amount of VSV-G expression vector, pMD-G (Ory et al.,
1996). Viral supernatants were harvested at 48 h post-
transfection, clarified by centrifugation (400×g for 5 min) and
0.45-μm filtration and used to infect human HeLa MAGI cells
or GHOST cells.
Viral growth assay
Viral supernatants were produced by transient transfection
of 293T cells and stored at −80 °C prior to infection.
Infection of MT4 cells or Jurkat cells was performed with
viral supernatants containing the indicated amounts of p24. At
24 h post-infection, cells were washed twice with growth
media to remove input viral antigens, and viral supernatants
were subsequently collected at 2-day intervals when cells
were split at a constant 1:3 dilution.
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